← Eichor
Study identifier: NCT07287098 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Condition: Breast Neoplasms  ·  Sponsor: Eli Lilly and Company

PhasePhase 2
Planned participants600
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days. Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.

This description comes directly from the study's public registry record.

Talk to the study team

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or  ·  1-317-615-4559  ·  LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact  ·  clinical_inquiry_hub@lilly.com

Always discuss trial participation with your own doctor first.

Locations (78)

University of Alabama at BirminghamBirmingham, Alabama, United StatesNot Yet Recruiting
Ironwood Cancer & Research CentersChandler, Arizona, United StatesSuspended
USC/Norris Comprehensive Cancer CenterLos Angeles, California, United StatesNot Yet Recruiting
UCLA Hematology/Oncology - ParksideSanta Monica, California, United StatesNot Yet Recruiting
Banner MD Anderson Cancer Center at North Colorado Medical CenterGreeley, Colorado, United StatesNot Yet Recruiting
Banner MD Anderson Cancer Center at McKee Medical CenterLoveland, Colorado, United StatesNot Yet Recruiting
AdventHealth Altamonte SpringsAltamonte Springs, Florida, United StatesNot Yet Recruiting
Winship Cancer InstituteAtlanta, Georgia, United StatesNot Yet Recruiting
Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana, United StatesRecruiting
University of Kentucky Chandler Medical CenterLexington, Kentucky, United StatesNot Yet Recruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesNot Yet Recruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesNot Yet Recruiting

+ 66 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07287098